Literature, news and videos pertinent to
The Mark Shames Research Advocacy Program

INHERIT EGFR - Studying Germline EGFR Mutations (INHERIT) —ClinicalTrials.gov

Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Corsello, S.M., Nagari, R.T., Spangler, R.D. et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer (2020) doi:10.1038/s43018-019-0018-6

Chemo-Sensitivity Testing for Lung Cancer:
Dr. Robert Nagourney & Ryan Kuper

 News feed below courtesy of MedWorm:

widget @ surfing-waves.com

The Mark Shames Research Advocacy Program is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.

For more information about this special program, please click on...

  1. Main
  2. About
  3. Photos
  4. Inspiration
  5. Tributes

Donate

We also accept PayPal™

paypal.me/ICANadvocacy



Guidestar Platinum Seal of Transparency 2021


Federal Tax I.D.: EIN 86-0818253